Founded by experts in biomolecular analysis, Ultivue is a venture-backed company developing reagent-driven solutions for high-definition biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. With technology licensed from Harvard and from Caltech., Ultivueâs proprietary reagents, instruments, and bioinformatics tools are designed to enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options. Ultivue's products are designed for fluorescent microscopy-based research judged to be of potentially major value for clinical diagnostic use. The company's patented technologies enable single molecule detection and visualization of a multitude of biomolecules, including proteins and nucleic acids, the key drivers of cellular functions and indicators of disease states
